The GSC performs primarily whole genome, transcriptome, and targeted amplicon sequencing and provides additional services in epigenomics, immunogenomics and metagenomics. The Centre also maintains a clinical cancer-sequencing pipeline accredited by the College of American Pathologists, enabling the rapid translation of research outcomes into timely and cost-effective applications in healthcare. In addition to health-related research, the GSC engages broadly in the life sciences more generally to support research in agriculture, environment, fisheries, forestry and the petroleum and mining sectors. Since its inception, the GSC participated in 521 grants and contracts totaling over $700 million, delivered collaborative services to over 1500 researchers and projects, and co-authored 722 manuscripts. They also contributed to international efforts to understand the human epigenome, microbiome, and the cancer genome. With the upcoming GIN funding, the GSC will continue to improve its ability to deliver high quality genome-scale data sets to the research community. In 2015, the GSC was awarded a Technology Development fund to expand upon several key areas for future growth in the genome sciences including 3rd generation sequencing methodologies, single cell analysis, exploitation of information rich but previously inaccessible sample types, and NGS approaches for studying adaptive immunity and facilitating the development of new immune based therapies.